# MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

> **NCT06840665** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** PD-1 antibody
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06840665
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2026-08-12
- **Final completion:** 2027-02-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840665, "MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06840665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*